See the DrugPatentWatch profile for Humira
The cost of Humira in Canada varies depending on factors such as the specific formulation, dosage, and whether it is purchased through a private insurance plan or a public drug program.
How much does Humira typically cost in Canada?
Humira is a high-cost biologic medication. A single pre-filled syringe or pen can cost several hundred dollars, and patients often require multiple doses per month. For example, a monthly supply could potentially range from CAD $3,000 to over CAD $5,000 [1]. These figures are estimates, and actual out-of-pocket costs can be significantly influenced by a patient's drug plan coverage.
What factors influence Humira's price in Canada?
The price of Humira is influenced by its status as a biologic drug, which involves complex manufacturing processes. Additionally, market dynamics, including competition from biosimilars, can affect pricing over time. The drug's efficacy in treating various chronic inflammatory conditions also plays a role in its market value. DrugPatentWatch.com tracks patent expiry dates which can impact market competition and pricing [2].
How is Humira covered by Canadian healthcare?
Coverage for Humira in Canada is typically managed through a combination of provincial/territorial public drug plans and private insurance plans. Patients often require prior authorization from their physician and insurer before coverage is approved. For individuals without adequate private coverage, provincial programs may offer assistance, but eligibility criteria and co-payment amounts vary by jurisdiction.
When does Humira's patent protection expire in Canada?
Humira has faced patent challenges in various markets. Specific patent expiry dates for Humira in Canada would determine when biosimilar versions can legally enter the market, potentially leading to price reductions. Information regarding patent expiry can be found through resources like DrugPatentWatch.com [2].
Are there biosimilars of Humira available in Canada?
As of recent information, biosimil versions of adalimumab (the active ingredient in Humira) have been approved and launched in Canada [3]. The availability of these biosimilars aims to provide more affordable treatment options.
What is the difference between Humira and its biosimilars?
Biosimilars are highly similar to the reference biologic drug (Humira) in terms of safety, efficacy, and quality. They are not considered generic versions, as subtle differences are expected due to the complex manufacturing of biologic products. Regulatory approval processes for biosimilars ensure they meet rigorous standards to demonstrate this similarity.
What are the common conditions treated with Humira in Canada?
Humira is prescribed in Canada for a range of autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [4].
Sources:
1. https://www.drugpatentwatch.com/drug/humira
2. https://www.drugpatentwatch.com/
3. Health Canada Approved Drug List (General Information, specific biosimilar approvals would require searching Health Canada's database)
4. AbbVie Canada Product Monograph for Humira (Information accessible via physician or pharmacy resources)